More recently, starting from the development of a novel anti-CD1a mAb, named UMG2, a monovalent BTCE that simultaneously binds CD1a on T-ALL cells and CD3ε on T-lymphocytes (CD1a x CD3ε) has been generated [64]. The gene discussed is CD1A; the disease is acute lymphoblastic leukemia.